A Preliminary Investigation of the Safety and Effectiveness of Oral Probiotics Supplementation for Reducing the Risk of Kidney Stone in Adults with Recurrent Kidney Stone Colic or Acute Episode of Colicky Pain: An Open-Label, Single-Arm, Prospective, Interventional, Proof-of-Science Study. 14 adults, with recurrent kidney stone colic or acute episode of colicky pain will be enrolled to ensure 12 subjects complete the study
Potential subjects will undergo screening based on predefined inclusion and exclusion criteria only after obtaining written informed consent. Subjects shall be instructed to visit the facility for the following scheduled visits: * Visit 01 \[Day 01\]: Screening, baseline evaluations, enrolment and test treatment dispensing. * Visit 02 \[Day 14 (± 2 days)\]: Treatment End, Follow-up Evaluations.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
14
Take one slow-release capsule twice a day, after meal.
Change in the colicky pain
Evaluate the effect of the test treatment in term of change in the colicky pain determined using the VAS scoring where 0 indicates no pain and 10 indicates severe pain
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Urine Calcium
Assessment of the effectiveness of the test treatment in terms of changes in Urine Calcium examined by urinalysis after 24h-urine collection
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Urine Sodium
Assessment of the effectiveness of the test treatment in terms of changes in Urine Sodium examined by urinalysis after 24h-urine collection
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Urine Oxalate
Assessment of the effectiveness of the test treatment in terms of changes in Urine Oxalate examined by urinalysis after 24h-urine collection
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Urine pH
Assessment of the effectiveness of the test treatment in terms of changes in Urine pH examined by urinalysis after 24h-urine collection
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Urine R/M
Assessment of the effectiveness of the test treatment in terms of changes in Urine R/M examined by urinalysis after 24h-urine collection
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Haemoglobin
Assessment of the safety of the test treatment in terms of abnormal changes in Haemoglobin
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Haematocrit
Assessment of the safety of the test treatment in terms of abnormal changes in Haematocrit.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Red Blood count
Assessment of the safety of the test treatment in terms of abnormal changes in Red Blood Count.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Packed Cell Volume
Assessment of the safety of the test treatment in terms of abnormal changes in Packed cell volume Count.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Red Blood count morphology
Assessment of the safety of the test treatment in terms of abnormal changes in Red Blood Count morphology.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Mean corpuscular volume
Assessment of the safety of the test treatment in terms of abnormal changes in Mean corpuscular volume
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in mean corpuscular hemoglobin
Assessment of the safety of the test treatment in terms of abnormal changes in mean corpuscular hemoglobin
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in mean corpuscular hemoglobin concentration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Assessment of the safety of the test treatment in terms of abnormal changes in mean corpuscular hemoglobin concentration
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in red blood cell distribution width
Assessment of the safety of the test treatment in terms of abnormal changes in red blood cell distribution width
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Total WBC count
Assessment of the safety of the test treatment in terms of abnormal changes in Total WBC count.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Differential WBC count
Assessment of the safety of the test treatment in terms of abnormal changes in Differential WBC count.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Platelet count
Assessment of the safety of the test treatment in terms of abnormal changes in Platelet count.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in mean platelet volume
Assessment of the safety of the test treatment in terms of abnormal changes in mean platelet volume.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Plateletcrit
Assessment of the safety of the test treatment in terms of abnormal changes in Plateletcrit.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in platelet distribution width
Assessment of the safety of the test treatment in terms of abnormal changes in platelet distribution width.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes inSerum Creatinine
Assessment of the safety of the test treatment in terms of abnormal changes in Serum Creatinine.
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Serum Glutamic Pyruvic Transaminase
Assessment of the safety of the test treatment in terms of abnormal changes in Serum Glutamic Pyruvic Transaminase
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).
Changes in Serum Glutamic-Oxaloacetic Transaminase
Assessment of the safety of the test treatment in terms of abnormal changes in Serum Glutamic-Oxaloacetic Transaminase
Time frame: On Day 01 (before administration) for baseline, and post-dosage on Day 14 (±2 days).